A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Trial details
- Registry ID
- NCT07465757
- Drugs studied
- Alisertib, Paclitaxel
TrialRedline tracks 4 clinical trials sponsored by Puma Biotechnology, Inc.: 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)NCT07465757 | Alisertib, Paclitaxel | Recruiting | 2028-03-31Estimated |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285 | Alisertib, Endocrine therapy | Recruiting | 2027-12-30Estimated |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerNCT06095505 | Alisertib | Recruiting | 2027-10-30Estimated |
| Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsNCT01953926 | Fulvestrant, Neratinib, Paclitaxel, Trastuzumab | Terminated | 2023-01-02Actual |
Names as written in the registry records.
NCT07465757 · Puma Biotechnology, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT06369285 · Puma Biotechnology, Inc.
Before: 150 participants (planned). After: 225 participants (planned).
Before: 30 Jun 2027. After: 30 Dec 2027.
NCT06095505 · Puma Biotechnology, Inc.
Before: 80 participants (planned). After: 120 participants (planned).
Before: 30 Apr 2027. After: 30 Oct 2027.